alanyl-glutaminyl-glycyl-valine
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02629874)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ala-gln-gly-val
- alanyl-glutaminyl-glycyl-valine
- aqgv tetrapeptide
- ea-230
- ea-230
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03145220 | Phase 2 | Jun 1, 2016 | Exponential Biotherapies Inc., Radboud University |
| NCT02629874 | Phase 1 | Feb 1, 2015 | Exponential Biotherapies Inc., Radboud University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exponential Biotherapies Inc. | For profit | 2 | 0 | 2 | 2015 |
| Radboud University | Academic/Hospital | 2 | 2 | 2 | 2015 |
2 organizations
Page 1 / 1